Aeglea Bio Therapeutics Stock Short Ratio
Aeglea Bio Therapeutics fundamentals help investors to digest information that contributes to Aeglea Bio's financial success or failures. It also enables traders to predict the movement of Aeglea Stock. The fundamental analysis module provides a way to measure Aeglea Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aeglea Bio stock.
Aeglea |
Aeglea Bio Therapeutics Company Short Ratio Analysis
Aeglea Bio's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Aeglea Bio Short Ratio | 2.84 X |
Most of Aeglea Bio's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aeglea Bio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
CompetitionBased on the latest financial disclosure, Aeglea Bio Therapeutics has a Short Ratio of 2.84 times. This is 27.18% lower than that of the Biotechnology sector and 61.67% lower than that of the Health Care industry. The short ratio for all United States stocks is 29.0% higher than that of the company.
Aeglea Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aeglea Bio's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aeglea Bio could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics of similar companies.Aeglea Bio is currently under evaluation in short ratio category among its peers.
Aeglea Fundamentals
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (94.85) % | |||
| Current Valuation | 228.21 M | |||
| Shares Outstanding | 4.05 M | |||
| Shares Owned By Insiders | 2.40 % | |||
| Shares Owned By Institutions | 97.60 % | |||
| Number Of Shares Shorted | 128.62 K | |||
| Price To Earning | (2.41) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 4.08 X | |||
| Revenue | 2.33 M | |||
| Gross Profit | (262 K) | |||
| EBITDA | (84.78 M) | |||
| Net Income | (83.81 M) | |||
| Cash And Equivalents | 73.68 M | |||
| Cash Per Share | 1.20 X | |||
| Total Debt | 4.63 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 4.65 X | |||
| Book Value Per Share | (60.61) X | |||
| Cash Flow From Operations | (80.14 M) | |||
| Short Ratio | 2.84 X | |||
| Earnings Per Share | (74.15) X | |||
| Target Price | 17.5 | |||
| Number Of Employees | 69 | |||
| Beta | 2.57 | |||
| Market Capitalization | 45.59 M | |||
| Total Asset | 71.14 M | |||
| Retained Earnings | (425.62 M) | |||
| Working Capital | 47.6 M | |||
| Current Asset | 38.29 M | |||
| Current Liabilities | 2.52 M | |||
| Z Score | -5.56 | |||
| Net Asset | 71.14 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |